Drug‐Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database
Open Access
- 3 February 2026
- journal article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (4) , 985-992
Abstract
Objectives: The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database. Methods: Using the WHO pharmacovigilance database, we identified cases using the Medical Dictionary for Regulatory Activities Preferred Term “Raynaud's phenomenon,” and we excluded all Individual Case Safety Reports (ICSRs) associated with at least one drug used in RP treatment. To estimate signals of disproportionate reporting (SDR), we calculated information component (IC) values (IC LB >0 deemed significant). We performed several sensitivity analyses to assess the robustness of the results. We evaluated and prioritized the plausibility of signals according to expert review of cases characteristics, robustness of results, and pharmacological hypotheses. Lastly, to explore pathophysiologic mechanisms, we used drug target extraction from DrugBank and a clustering method to identify similar patterns of adverse events reporting. Results: We included 4,430 ICSRs of RP in our analysis. We found 124 significant SDRs in the primary analysis, of which 52 SDRs were consistent across all sensitivity analyses, and 16 were considered probable after signal evaluation and prioritization, including amphetamine‐like, antimigraine drugs, antineoplastics drugs, and dopaminergic agonists. Most of the targets involved were 5‐HT1A receptors, sodium‐dependent noradrenaline transporters, and beta‐1 and beta‐2 adrenergic receptors. Cluster analyses yielded inconsistent results according to the method used. Conclusion: This study allowed us to identify robust safety signals (such as solriamfetol, tyrosine kinase inhibitors, and calcitonin gene‐related peptide inhibitors) for drugs associated with RP and potential implicated pathophysiologic mechanisms. imageKeywords
This publication has 35 references indexed in Scilit:
- Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting SystemDrug Safety, 2024
- The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and StatementDrug Safety, 2024
- The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and ElaborationDrug Safety, 2024
- Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud PhenomenonJAMA Network Open, 2021
- A Comparison Study of Algorithms to Detect Drug–Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning ApproachesDrug Safety, 2019
- Pilot evaluation of an automated method to decrease false‐positive signals induced by co‐prescriptions in spontaneous reporting databasesPharmacoepidemiology and Drug Safety, 2013
- A Bayesian neural network method for adverse drug reaction signal generationEuropean Journal of Clinical Pharmacology, 1998
- The effects of single oral doses of 17β-oestradiol and progesterone on finger skin circulation in healthy women and in women with primary Raynaud's phenomenonEuropean Journal of Clinical Pharmacology, 1994
- Deficiency of calcitonin gene-related peptide in Raynaud's phenomenonThe Lancet, 1990
- Prevalence of Raynaud's Phenomenon in Patients With MigraineArchives of internal medicine (1960), 1984